Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 673-683

  Chu, Xiao Yan ^a   Bleasby, Kelly ^a   Yabut, Jocelyn ^a   Cai, Xiaoxin ^a   Chan, Grace Hoyee ^a   Hafey, Michael J ^a   Xu, Shiyao ^a   Bergman, Arthur J ^a   Braun, Matthew P ^a   Dean, Dennis C ^a   Evers, Raymond ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; CIMETIDINE; CYCLOSPORIN A; DIGOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; ENALAPRILAT; FENOFIBRATE; FENOFIBRIC ACID; FUROSEMIDE; GABAPENTIN; GLYCOPROTEIN P; IBUPROFEN; INDAPAMIDE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; ORGANIC ANION TRANSPORT POLYPEPTIDE 4C1; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 3; ORGANIC CATION TRANSPORTER 2; PEPTIDE TRANSPORTER 1; PROBENECID; QUINAPRIL; QUINIDINE; RITONAVIR; SITAGLIPTIN; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; KIDNEY PROXIMAL TUBULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; WESTERN BLOTTING;

ADENOSINE DEAMINASE; ANIMALS; ANTIGENS, CD26; BIOLOGICAL TRANSPORT; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME INHIBITORS; GLYCOPROTEINS; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; P-GLYCOPROTEIN; PYRAZINES; TRIAZOLES;

EID: 34247236764     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.116517     Document Type: Article

References (40)

1. Albert KS and Gernaat CM (1984) Pharmacokinetics of ibuprofen. Am J Med 13: 40-46.
2. Arafat T, Awad R, Hamad M, Azzam R, Al-Nasan A, Jehanli A, and Matalka K (2005) Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. J Clin Pharm Ther 30:319-328.
3. Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, Xu S, Elmore CS, Ciccotto S, Hora DF, et al. (2007) Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos, in press.
4. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, et al. (2006) Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28:55-72.
5. Bergman A, Krishna R, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, et al. (2005) Lack of a pharmacokinetic food effect and evaluation of the definitive bioavailability of sitagliptin (MK-0431), an oral dipeptidyl peptidase-IV inhibitor. J Clin Pharmacol 45:1089.
6. Breslin E, Posvar E, Neub M, Trenk D, and Jahnchen E (1996) A pharmacodynamic and pharmacokinetic comparison of intravenous quinaprilat and oral quinapril. J Clin Pharmacol 36:414-421.
7. Blum RA, Comstock TJ, Sica DA, Schultz RW, Keller E, Reetze P, Bockbrader H, Tuerck D, Busch JA, and Reece PA (1994) Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 56:154-159.
8. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, and Sweet DH (1999) The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 56:570-580.
9. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, and Endou H (2001) Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59:1277-1286.
10. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJ, and Jaffe HS (1995) Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 39:1247-1252.
11. Charbonnel B, Karasik A, Liu J, Wu M, Sanchez M, and Meininger G (2006) Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled on metformin alone. Diabetes Care 29:2638-2643.
12. Deacon CF (2005) MK-431 (Merck). Curr Opin Investig Drugs 6:419-426.
13. Fujita T, Urban TJ, Leabman MK, Fujita K, and Giacomini KM (2006) Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 95:25-36.
14. Gustavson LE, Schweitzer SM, Burt DA, Achari R, Rieser MJ, Edeki T, Chira T, Yannicelli HD, and Kelly MT (2006) Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: a phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Clin Ther 28:373-387.
15. Grebow PE, Treitman JA, Barry EP, Blasucci DJ, Portelli ST, Tantillo NC, Vukovich RA, and Neiss ES (1982) Pharmacokinetics and bioavailability of indapamide-a new antihypertensive drug. Eur J Clin Pharmacol 22:295-299.
16. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, et al. (2005) Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78:675-688.
17. Herman GA, Bergman A, Yi B, Kipnes M; The Sitagliptin Study 012 Group (2006) Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 22:1939-1947.
18. Hediger MA, Johnson RJ, Miyazaki H, and Endou H (2005) Molecular physiology of urate transport. Physiology (Bethesda) 20:125-133.
19. Hardman JG and Limbird LE (2001) The Pharmacological Basis of Therapeutics, 10th ed., McGraw-Hill Book Companies, New York.
20. Kieffer TJ and Habener JF (1999) The glucagon-like peptides. Endocr Rev 20:876-913.
21. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, et al. (2005) (2R)-4-Oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl] -1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 13:141-151.
22. Krishna R, Bergman A, Larson P, Cote J, Lasseter K, Dilzer S, Wang A, Zeng W, Chen L, Wagner J, et al. (2007) Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects. J Clin Pharmacol 47:165-174.
23. Lee W and Kim RB (2004) Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 44:137-166.
24. Li M, Anderson GD, and Wang J (2006) Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin Drug Metab Toxicol 2:505-532.
25. Launay-Vacher V, Izzedine H, Karie S, Hulot JS, Baumelou A, and Deray G (2006) Renal tubular drug transporters. Nephron Physiol 103:97-106.
26. Miller J, Migoya E, Talaty J, Bergman AJ, Xu Y, Zheng W, Guiterrez M, Wagner J, and Herman GA (2006) The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects: results of a multiple-dose, double-blind, randomized, placebo-controlled study. Clin Pharmacol Ther 79:24.
27. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, and Inui K (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866-874.
28. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, et al. (2004) Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 101:3569-3574.
29. Omote H, Hiasa M, Matsumoto T, Otsuka M, and Moriyama Y (2006) The MATE Proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol Sci 27:587-593.
30. Robertson EE and Rankin GO (2006) Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. Pharmacol Ther 109:399-412.
31. Selen A, Amidon GL, and Welling PG (1982) Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci 71:1238-1242.
32. Shitara Y, Sato H, and Sugiyama Y (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45:689-723.
33. Tanigawara Y (2000) Role of P-glycoprotein in drug disposition. Ther Drug Monit 22:137-140.
34. Tahara H, Kusuhara H, Endou H, Koepsell H, Imaoka T, Fuse E, and Sugiyama Y (2005) A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 315:337-345.
35. Terada T and Inui K (2004) Peptide transporters: structure, function, regulation and application for drug delivery. Curr Drug Metab 5:85-94.
36. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, and Tsuji A (2000) Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273:251-260.
37. van Crugten J, Bochner F, Keal J, and Somogyi A (1986) Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. J Pharmacol Exp Ther 236:481-487.
38. 14C]sitagliptin in humans. Drug Metab Dispos, in press.
39. Wright SH and Dantzler WH (2004) Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 84:987-1049.
40. Yamazaki M, Li B, Louie SW, Pudvah NT, Stocco R, Wong W, Abramovitz M, Demartis A, Laufer R, Hochman JH, et al. (2005) Effects of fibrates on human organic anion-transporting polypeptide 1B1-,multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 35:737-753.